Close Menu

KIF6

While Celera can potentially add to Quest's biomarker discovery capabilities and cardiovascular disease testing pipeline, private payors are still not reimbursing for a large share of Celera's products, which may impact how quickly Quest can see a return on its investment.

UCSF will use Celera's KIF6 genetic variant discoveries to develop a test for cardiovascular risk and statin benefit.

Medco wants to know if a gene variant test could predict patient adherence to statin treatment.

Milwaukee-based Aurora Health Care will use Celera's KIF6 test in its heart health programs.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.